Best Biopharma Outsourcing Companies in San Francisco, United States
The 63 best Biopharma Outsourcing companies in San Francisco, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Kardigan.
Our analysis of 50 Biopharma Outsourcing companies
$6.3b in tracked funding; 77% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Biopharma Outsourcing companies in San Francisco
| # | Company | Disclosed funding | Employees | Founder | Founded | Stage | Web popularity | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Kardigan Biotech company developing personalized medicines for cardiovascular diseases 60Funding top 14%Growth top 28%Tech top 48%Talent bottom 49% All 6 signals ▾Fundingtop 14% Growthtop 28% Techtop 48% Talentbottom 49% Marketbottom 35% Globalbottom 33% Funding: Raised $554M across 2 rounds · 2 rounds over 1 yrs (2.0/yr) Growth: Web rank 10,000,000 → 5,000,000 YoY · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 60/100 | $554M | — | Tassos Gianakakos Co-Founder & CEO | 2023 | Series B | Top 5M | — | 1 job opening · 1 internship |
| 2 | Surrozen Pioneering targeted regenerative antibodies to repair tissue and restore organ function 19Product top 14%Funding top 24%News top 33%Moat top 41% All 11 signals ▾Producttop 14% Fundingtop 24% Newstop 33% Moattop 41% Innovationtop 48% Patentstop 48% Growthbottom 46% Globalbottom 40% Marketbottom 29% Fin. healthbottom 20% Techbottom 15% Product: 11 distinct product lines · Company stage: Public Funding: Raised $326M across 5 rounds · 5 rounds over 9 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 19/100 | $326M | 80 | — | 2016 | Public | — | 37 patents Therapeutic Wnt pathway modulators and antibodies for ocular disease treatment | — |
| 3 | Vial | $100M | 65 65 → 155 (+138%) | Simon Burns Co-Founder & CEO | 2020 | Series B | Top 10M | — | — |
| 4 | AllStripes Provider of information to patients and communities with the medical data for rare diseases | $67M | 85 | — | 2017 | Acquired | — | — | — |
| 5 | 64x Bio Developer of cell lines and production technologies for advanced therapies | $60M | 18 18 → 21 (+17%) | David Thompson Co-Founder | 2017 | Series A | — | — | 2 launchs |
| 6 | Altheos R&D company focused on manufacturing drugs for multiple therapeutic areas | $32M | — | Henry H. Hsu CEO | 2010 | Deadpooled | — | — | — |
| 7 | Amber Bio CDMO focused on manufacturing generic drugs | $26M | 9 | Jacob Borrajo Co-Founder & CEO | 2021 | Seed | Top 50M | — | — |
| 8 | BioSeek Global leader providing comprehensive laboratory testing services across diverse industries | $19M | — | Ellen Berg Co-Founder | 2000 | Acquired | — | 39 patents Computational genomics and patient classification for disease profiling and functional homology screening | — |
| 9 | Serotiny Provider of drug research and development services for cell & gene therapies | $7M | 12 | — | 2009 | Series A | — | 12 patents Engineered conditional immune cell receptors for targeted immunotherapy applications. | — |
| 10 | BioZone Laboratories Developer and manufacturer of finished dosage forms | $6M | 93 | Brian Keller Co-Founder & CSO | 1987 | Series A | — | — | — |
| 11 | Cromatic Provider of a digital connectivity platform for matching clients with CROs | $5M | 10 | Ann Lin CEO | 2022 | Seed | Top 50M | — | — |
| 12 | Trial Library Provider of clinical trial for drug research & development services 29Growth top 35%Funding top 43%Tech top 50%Global bottom 36% All 5 signals ▾Growthtop 35% Fundingtop 43% Techtop 50% Globalbottom 36% Marketbottom 13% Growth: Fresh capital in last 24 mo Funding: Raised $5.0M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) rank vs industry peers · Fliar Intelligence Index 29/100 | $5M | 9 | — | 2018 | Series A | Top 50M | — | 1 job opening |
| 13 | Crescendo Health Platform enabling clinical study participants to assemble and contribute health data | $3M | 20 | Sam Roosz Co-Founder / CEO | 2021 | Seed | Top 50M | — | — |
| 14 | Optivia Biotechnology CRO offering transporter screening services and solutions for DDI, DMPK, safety and pharmacology | $3M | — | Peter Milner Co-Founder | 2007 | Acquired | — | — | — |
| 15 | Strategikon Provider of SaaS solutions for clinical trial management | $2M | — | Paulo Carvalho Co-Founder & COO | 2017 | Series A | — | — | — |
| 16 | Validant Provider of regulatory, compliance, and quality consulting services for GxP product lifecycles | $2M | 237 | — | 2005 | Acquired | Top 50M | — | — |
| 17 | SUPERFLUID Company specializing in translational science and data analysis for molecular diagnostics and tissue and… | $2M | — | Gajus Worthington CEO | 2015 | Series A | — | 2 patents Detecting splice junctions in extracellular cell‑free mRNA using bioinformatics platforms | — |
| 18 | Aratome High-throughput proteomic imaging tool | $1M | 4 | Jay Trautman Co-Founder & Director | 2011 | Funding Raised | — | 21 patents Ligase‑based nucleic acid amplification for sensitive molecular diagnostics | — |
| 19 | Anto Biosciences Developer of microbiology tools to improve food and drug design | $500K | — | Arvid Gollwitzer Co-Founder | 2025 | Seed | — | — | — |
| 20 | MatterShift CRO focused on manufacturing of membrane based drugs | $500K | 1 | — | 2013 | Seed | — | — | — |
| 21 | Biomerix Corporation Innovating health, nutrition, and care solutions with biomaterials and scientific expertise | $400K | 13 | Peter Costantino Co-Founder | 2001 | Funding Raised | — | 85 patents Patents concentrated in health & consumer products | — |
Top 12 Biopharma Outsourcing companies in San Francisco
#1
Series B · San Francisco, California · founded 2023$554Mraised▾
Biotech company developing personalized medicines for cardiovascular diseases. It is a biotechnology company focused on developing precision medicines for cardiovascular disease. The company aims to modernize cardiovascular drug development with a late-stage portfolio of personalized medicines.
- Oct 2025Series B$254M
- Jan 2025Series A$300M
#2
Public · San Francisco, California · founded 2016 · 80 employees$326Mraised▾
Pioneering targeted regenerative antibodies to repair tissue and restore organ function. This company is developing a new class of therapeutics focused on tissue regeneration. Through selective activation of the Wnt pathway with targeted antibodies, they aim to treat serious diseases characterized by tissue injury. They design tissue-specific antibodies that engage the body’s own biological repair mechanisms, developing a pipeline of first-in-class drug candidates. Their platform promises to overcome limitations of regenerative medicines. Combining Wnt pathway biology understanding with advanced antibody engineering, they design tissue-specific antibodies with the potential to regenerate tissue across various organs and tissues. They are currently focused on Ophthalmology, addressing severe eye diseases. Their uniquely-engineered antibodies selectively modulate the Wnt pathway to repair tissue damage and improve organ function. Their vision is to engage the body’s own biological tissue repair mechanisms with their targeted regenerative antibodies.
- Mar 2025Post IPO$175M
- Apr 2024Post IPO$193M
- Jun 2020Series C$50M
- Mar 2019Series B$50M
#3
Series A · San Francisco, California · founded 2018 · 9 employees$5Mraised▾
Provider of clinical trial for drug research & development services
- Dec 2025Series A$10M
- Aug 2022Seed$5M
#4
Series A · San Francisco, California · founded 2017$2.3Mraised▾
Provider of SaaS solutions for clinical trial management. These solutions streamline clinical trial processes, focusing on financial management, vendor management, and procurement. The offerings automate budgeting, RFP/RFI management, contract generation, and vendor qualification, improving efficiency and reducing costs. The platform provides real-time insights into trial finances and vendor performance, enabling data-driven decision-making. Services include consulting, managed services, and implementation support to ensure successful adoption and ongoing operational excellence.
- May 2025Venture Debt$2.3M
- Apr 2021Series A—
#5
Seed · San Francisco, California · founded 2025$500Kraised▾
Developer of microbiology tools to improve food and drug design. The company provides data and tools for other companies. These resources are intended to improve the design of both food and drugs. The tools leverage microbiology to provide insights.
- Sep 2025Seed$500K
#6
Series B · San Francisco, California · founded 2020 · 65 employees$100Mraised▾
- Dec 2022Series B$67M
#7
Seed · San Francisco, California · founded 2021 · 9 employees$26Mraised▾
CDMO focused on manufacturing generic drugs
- Aug 2023Seed$26M
#8
Series A · San Francisco, California · founded 2017 · 18 employees$59.6Mraised▾
Developer of cell lines and production technologies for advanced therapies. They engineer high yield cell lines and production technologies. The company focuses on accelerating the manufacturing of advanced therapies. Their platform is designed to unlock the scale needed for next generation medicines. The company offers cell line optimization for lentivirus manufacturing and a wide range of biologics.
- Jan 2022Series A$55M
- Nov 2020Seed$4.5M
- 2018Seed$150K
#9
Acquired · San Francisco, California · founded 2017 · 85 employees$67Mraised▾
AllStripes provides information to patients and communities for medical data for rare diseases. It offers patient information like regulatory evidence for drug, medical data science, research in rare diseases, rare disease programs. It offers solutions for diseases like Wilson disease, Sanfilippo syndrome, SURF1 among others.
- Aug 2021Series B$50M
- Apr 2020Series A$14M
- Aug 2018Seed$3M
#10
Seed · San Francisco, California · founded 2022 · 10 employees$5.3Mraised▾
Provider of a digital connectivity platform for matching clients with CROs. It is an online platform that helps life science innovators find and connect with R&D outsourcing partners for clinical research and development in the life sciences industry. It provides access to a network of CROs that offer non-clinical, preclinical, and clinical services. The features include outsourcing requests management, collaboration and communication management, manage quotations, schedule video calls, payments processing, document tracking, and more. It is a tool available on the subscription based pricing model.
- Nov 2023Seed$5.3M
#11
Series A · San Francisco, California · founded 2009 · 12 employees$7Mraised▾
Provider of drug research and development services for cell & gene therapies
- Mar 2023Series A$4M
- Jul 2018Seed$3M
- Jan 2016Grant (prize money)$150K
#12
Series A · San Francisco, California · founded 2015$1.9Mraised▾
Superfluid Dx is a company that is focused on building a translational science and data analysis platform. They specialize in circulating RNA and molecular diagnostics, particularly in relation to tissue and organ health.
- Dec 2023Series A—
- Sep 2023Grant (prize money)$1.9M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Biopharma Outsourcing coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in the United States
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 6,260 United States-affiliated papers.
- Harvard University209
- Cornell University177
- University of Tennessee at Chattanooga140
- Howard Hughes Medical Institute126
- Johns Hopkins University121
- Gene33→164
- Transcription (linguistics)11→79
- Antibody11→62
- Genome6→56
- Mutation7→56
- Gene8→110
- Cell culture3→62
- Gene expression3→62
- Fermentation2→54
- Downregulation and upregulation1→50
- Agriculture19→58
- Antibiotic resistance15→45
- Public health4→31
- Gene6→30
- Production (economics)5→29
Where biotechnology is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing biotechnology patents in the United States
United States biotechnology patent filing is accelerating — 457,918 filings from 8,000 assignees (2016–2025), led by Genentech, UNIV California, Regeneron Pharma; annual filings 36884→44446.
- Genentech18078
- UNIV California17948
- Regeneron Pharma16082
- Amgen10495
- Monsanto Technology9742
- UNIV Pennsylvania8521
- Harvard College7460
- UNIV Texas7378
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.